摘要:
Cripto, a developmental oncoprotein, antagonizes activin and TGF-β signaling by forming a complex with activin and TGF-β and their type II receptors. This complex precludes the formation of a functional activin/TGF-β•type II•type I complex, thereby blocking the signaling of activin and TGF-β. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-β complex may enhance antiproliferative effects of activin and TGF-β.
摘要:
Cripto, a developmental oncoprotein, antagonizes activin and TGF-β signaling by forming a complex with activin and TGF-β and their type II receptors. This complex precludes the formation of a functional activin/TGF-β•type II•type I complex, thereby blocking the signaling of activin and TGF-β. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-β complex may enhance antiproliferative effects of activin and TGF-β.